WHO today validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use, giving countries, funders, procuring agencies and communities the assurance that it meets international standards for safety, efficacy and manufacturing. The vaccine, which is produced by the Beijing-based pharmaceutical company Sinovac is now included in WHO’s Emergency Use Listing (EUL).
The Sinovac-CoronaVac product is an inactivated vaccine. Its easy storage requirements make it very manageable and particularly suitable for low-resource settings.
Vaccine efficacy results showed that the vaccine prevented symptomatic disease in 51% of those vaccinated and prevented severe COVID-19 and hospitalization in 100% of the studied population.
WHO recommends the vaccine for use in adults 18 to 60 years old. Despite WHO is not recommending an upper age limit for the vaccine based on the data available there is no reason to believe that the vaccine has a different safety profile in older and younger populations.
Being included in the EUL the Sinovac-CoronaVac COVID-19 vaccine is elligible for the COVAX Facility vaccine supply and international procurementand for countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.
“The world desperately needs multiple COVID-19 vaccines to address the huge access inequity across the globe,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. “We urge manufacturers to participate in the COVAX Facility, share their knowhow and data and contribute to bringing the pandemic under control.”